Analysis of market scale and competition of China Biomedical Industrial Park
Introduction: China Biomedical Industrial Park is constantly developing with the development of advanced innovation development zones. In the early 1990s, the country made a strategic decision to accelerate the development of advanced innovative technology industries. As of the end of 2019, there were 193 biomedical industrial parks in China, accounting for 49.87%, mainly in Jiangsu, Shandong, and Guangdong. The cumulative number of biomedical industrial parks in the three places reached 40, accounting for 21% of the national total. The TOP10 distribution area of the biomedical industrial park is relatively scattered, and Shanghai Zhangjiang High-tech Industrial Development Zone ranks first.
In recent years, the scale of the output value of my country's biomedical parks has been increasing year by year, with an average annual compound growth rate of 11%. The scale of the output value in 2019 is 2.2 trillion yuan. The vast majority of domestic biopharmaceutical park enterprises have weak innovation output, and only a few parks are actively applying for Class 1 new drugs.
By the end of 2019, there were 193 biomedical industrial parks in my country, accounting for 49.87%
According to statistics, as of the end of 2019, there were 168 national-level high-tech zones and 219 national-level economic and technological development zones, with a total of 387 national-level industrial parks. Among them, 193 take the bio-pharmaceutical industry as the key development direction, accounting for 49.87%.
my country's top 100 biopharmaceutical industrial parks are mainly concentrated in Jiangsu, Shandong, and Guangdong. The cumulative number of biomedical industrial parks in the three places has reached 40, accounting for 21% of the national total.
According to statistics, China's top 100 biopharmaceutical industrial parks are mainly concentrated in Jiangsu, Shandong, and Guangdong. The cumulative number of biomedical industrial parks in the three places has reached 40, accounting for 21% of the national total; the number of biomedical industrial parks in Hubei and Zhejiang is There are 6 bio-pharmaceutical industrial parks in Hunan, Jilin and Tianjin areas.
2020 my country's biomedical industrial park TOP10 distribution area is relatively scattered, Shanghai Zhangjiang High-tech Industrial Development Zone ranks first
According to CCID data, the TOP10 distribution areas of my country's biomedical industrial park in 2020 are relatively scattered. Shanghai Zhangjiang Hi-Tech Industrial Development Zone ranks first, Suzhou Industrial Park and Zhongguancun Science Park rank second and third respectively.
The scale of the output value of my country's biomedical parks has been increasing year by year, with an average annual compound growth rate of 11%. The scale of the output value in 2019 is 2.2 trillion yuan
From 2017 to 2019, the scale of the output value of my country's biopharmaceutical parks has been increasing year by year, with an average annual compound growth rate of 11%. In 2019, the scale of my country's biomedical park output value was 2.2 trillion yuan, an increase of 12.9% year-on-year. According to CCID data, the output value of my country's biomedical parks will reach 2.5 trillion yuan by 2020.
The vast majority of domestic biopharmaceutical park companies have weak innovation output, and only a few parks are actively applying for Class 1 new drugs
The vast majority of domestic biopharmaceutical park enterprises have weak innovation output, and only a few parks are actively applying for Class 1 new drugs. In 2019, there were only 11 parks with more than 10 class 1 new drug declarations, and there was a wide gap in the number of class 1 new drug declarations between the parks.
The biopharmaceutical industrial parks with more outstanding new drug declarations in 2019 are mainly Suzhou Industrial Park, Shanghai Zhangjiang High-tech Industrial Development Zone and Lianyungang Economic and Technological Development Zone, with more than 60 declarations.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Visitor Pre-Registration is Now Open for analytica Shanghai 2026
-
China's Fixed-Asset Investment Up 3.8% YoY in H1 2023, Led by Chemical Industry
-
In the First Half of the Year, the Manufacturing Price of Chemical Raw Materials and Products Increased by 16.3% Year-on-year
-
Structure Of Supply Chain Of Pharmaceutical Products
-
In The First Four Months, The Investment in Chemical Raw Materials and Products Manufacturing Industry Increased by 16.2% Year-on-year
-
The Added Value of Chemical Raw Materials And Products Manufacturing in April Fell by 0.6% Year-on-year
-
In April, the Prices of Chemical Raw Materials and Products Increased by 14.9% Year-on-year and 1.4% Month-on-month.
-
The Latest Data! Total Retail Sales of Cosmetics Fell 6.3% in March
-
The Added Value of Chemical Raw Materials And Products Manufacturing In March Increased By 3.0% Year-on-year
-
If Crude Oil Plummets, Which Chemical Products Will Be 'Unbearable' First?
Recommend Reading
-
Chemical Tanker Explodes Off Oman Coast, Maritime Security Risk Escalates Again
-
Hormuz Sees at Least 12 Vessel Incidents in One Week as Traffic Falls to Two-Month Low
-
Saudi Aramco’s 400,000 bpd Jazan Refinery Shuts After Attack
-
When SWIFT Goes On-Chain: A New 24/7 Order for Cross-Border Payments
-
Japan Extends Bisphenol A Anti-Dumping Probe, Prolonging Uncertainty for Korean and Taiwanese Suppliers
-
Business Society September 23, 2026 Isooctanol Trend Analysis: Bearish Bias
-
Premium Global Chemical Sourcing Requests (2-7Oct.,2026)
-
Business Society, September 23, 2026: Acrylic Acid Trend Analysis — Clear Decline
-
This Week's Epichlorohydrin Market Trading Focus Downward (11.3-11.6)
-
Multiple cycles at all-time lows! Melamine to remain in a narrow, weakly oscillating range in the short term